Furthermore, the effect of FXa inhibitor rivaroxaban on clinical outcomes was recently tested in the COMMANDER HF (“A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure”) trial [40]. Here, F10 is linked to Stroke.